
About S S ORGANICS
S S ORGANICS is a publicly listed company based in Hyderabad (India) founded in 1990. Finished products and APIs are manufactured for therapeutic categories. The company has 98 employees. Its chief executive, as recorded, is V N Sunanda Reddy. Its Indian entity Oxygenta Pharmaceutical Limited reported revenue of βΉ113 Cr. Its focus areas include Biopharma Outsourcing, CDMO and Small Molecules & Peptides. Similar companies include Indoco Remedies, Concord Biotech and BDR Pharmaceuticals Internationals; 1 of its 3 listed similar companies has raised funding.
Company details
SS Organics was founded in 1990 in Hyderabad, India, within the pharmaceutical sector. Finished products and active pharmaceutical ingredients (APIs) are produced across categories such as antibiotics, analgesics, respiratory, cardiovascular, gastrointestinal, and antifungal treatments. Manufacturing facilities are certified under ISO 9001:2000 standards, supporting operations focused on these therapeutic areas.
- Headquarters Hyderabad, India
- Employees 98
- Stage Public
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website ssorganics.co.in
- Legal Name S.S. Organics Ltd.
- Date of Incorporation 27 Nov, 1990
- Jurisdiction Medak, Telangana, India
- Market Cap₹181 Cr
OXYGENTAPH · BSE
- Share Price₹50.49
+3.10% today
- Revenue₹113 Cr
FY 2025-26 · +3.4% YoY
- EBITDA−₹15.32 Cr
Margin -13.6%
- Net Profit−₹17.56 Cr
FY 2025-26 · -69.7% YoY
- Employee Count98
Associated legal entities of S S ORGANICS
S S ORGANICS operates through Oxygenta Pharmaceutical Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Oxygenta Pharmaceutical Limited Listed CIN L24110TG1990PLC012038 | Active | 27 Nov 1990 | Medak, Telangana | ₹113 Cr | 98 | 10 | View details |
Board of directors of Oxygenta Pharmaceutical Limited (S S ORGANICS)
Oxygenta Pharmaceutical Limited is the primary company behind S S ORGANICS. The board of Oxygenta Pharmaceutical Limited currently have 8 directors; the longest-serving is Vedavathi Gangavaram, appointed in 2025. 41 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Vedavathi Gangavaram DIN 02870966 | Director | 20 Jun 2025 | 1 yr 4 mo | Oxygenta Pharmaceutical Limited |
| Veera Reddy Arava DIN 10832178 | Director | 20 Jun 2025 | 1 yr 4 mo | Oxygenta Pharmaceutical Limited |
| Sidda Reddy Kanuparthi DIN 07156289 | Director | 20 Jun 2025 | 1 yr 4 mo | Oxygenta Pharmaceutical Limited |
| Sharvari Swapnil Shinde DIN 11149764 | Director | 20 Jun 2025 | 1 yr 4 mo | Oxygenta Pharmaceutical Limited |
| Chandra Mouliswar Reddy Gangavaram DIN 00046845 | Whole-time director | 20 Jun 2025 | 1 yr 4 mo | Oxygenta Pharmaceutical Limited |
| Balasubba Reddy Mamilla DIN 01998852 | Whole-time director | 20 Jun 2025 | 1 yr 4 mo | Oxygenta Pharmaceutical Limited |
| Janardhana Reddy Yeddula DIN 03207357 | Additional Director | 23 May 2026 | 5 mo | Oxygenta Pharmaceutical Limited |
| Amireddy Venkatesu Reddy DIN 11087687 | Additional Director | 23 May 2026 | 5 mo | Oxygenta Pharmaceutical Limited |
People of S S ORGANICS
1 people are tracked at S S ORGANICS (1 in leadership); the tracked headcount is 98.
| Name | Role | Group |
|---|---|---|
V N Sunanda Reddy | CEO & MD | Leadership |
Complete people profiles for S S ORGANICS
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of S S ORGANICS
S S ORGANICS is a publicly listed company on the BSE with ticker symbol OXYGENTAPH in India, operating in the Pharmaceuticals sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date23 Jul 2021
- Listed onBSE: 524636
- Listed entityOxygenta Pharmaceutical Limited
- Exchange sectorPharmaceuticals
Financials of S S ORGANICS
Exchange-reported figures of Oxygenta Pharmaceutical Limited, the listed company behind S S ORGANICS (BSE: OXYGENTAPH).
Financial Highlights
FY 2025-26 Β· StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 113 | 109 | 39.64 | 30.99 | 60.52 | 52.03 | 13.72 |
| Revenue growth | +3.4% | +175.7% | +27.9% | -48.8% | +16.3% | +279.2% | - |
| EBITDA | (15.32) | (9.82) | (9.71) | (7.97) | 0.67 | 3.85 | (7.86) |
| EBITDA margin | -13.6% | -9.0% | -24.5% | -25.7% | +1.1% | +7.4% | -57.3% |
| Profit before tax | (22.17) | (14.35) | (13.86) | (11.37) | (0.48) | 3.15 | (5.93) |
| Net profit | (17.56) | (10.35) | (3.51) | (10.85) | (1.03) | 0.90 | (9.77) |
| Net profit margin | -15.5% | -9.5% | -8.9% | -35.0% | -1.7% | +1.7% | -71.2% |
| EPS (βΉ) | (4.75) | (2.78) | (1.04) | (8.15) | (0.43) | 2.87 | (5.67) |
| Balance sheet | |||||||
| Total assets | 67.86 | 37.67 | 37.73 | 25.45 | 22.73 | 17.88 | 3.12 |
| Net worth | (42.69) | (25.64) | (20.13) | (46.20) | (34.63) | (38.02) | (40.95) |
| Total debt | 110 | 62.23 | 57.23 | 68.00 | 52.13 | 47.89 | 26.92 |
| Cash & bank | 2.15 | 0.12 | 0.10 | 0.11 | 0.16 | 0.45 | 0.12 |
| Net working capital | (0.40) | (14.20) | (1.35) | (2.13) | 2.58 | 1.29 | (8.72) |
| Cash flow | |||||||
| Cash from operations | (27.75) | 2.83 | (13.05) | (1.63) | (1.68) | (1.62) | (2.59) |
| Cash from investing | (14.39) | (11.32) | (4.09) | (9.64) | (4.94) | (6.72) | (0.50) |
| Cash from financing | 42.56 | 8.49 | 17.13 | 11.22 | 6.33 | 8.67 | 3.19 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 33.49 | 37.00 | 49.61 | 33.93 | 14.30 | 15.13 | 49.47 | 33.21 |
| Revenue growth (YoY) | +134.2% | +144.6% | +0.3% | +2.2% | +2.1% | +19.9% | - | - |
| Other income | 0.02 | 0.02 | 0.17 | 0.00 | (0.06) | 0.17 | 0.05 | 0.49 |
| Total expenses | 33.47 | 36.45 | 49.50 | 38.01 | 18.88 | 21.98 | 51.42 | 37.56 |
| EBITDA | 0.02 | 0.55 | 0.11 | (4.08) | (4.58) | (6.85) | (1.95) | (4.35) |
| EBITDA margin | +0.1% | +1.5% | +0.2% | -12.0% | -32.0% | -45.3% | -3.9% | -13.1% |
| Depreciation | 0.71 | 0.62 | (0.24) | 0.86 | 0.86 | 0.85 | (0.23) | 0.71 |
| Interest | 2.73 | 2.46 | 1.81 | 1.39 | 0.95 | 0.63 | 2.13 | 0.39 |
| Profit before tax | (3.40) | (2.51) | (1.29) | (6.33) | (6.45) | (8.16) | (3.80) | (4.96) |
| Tax | (0.66) | (0.40) | 0.42 | (1.48) | (1.51) | (2.04) | (1.65) | (1.03) |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 33.49 | 37.00 | 49.61 | 33.93 | 14.30 | 15.13 | 49.47 | 33.21 |
| Revenue growth (YoY) | +134.2% | +144.6% | +0.3% | +2.2% | +2.1% | +19.9% | - | - |
| Other income | 0.02 | 0.02 | 0.17 | 0.00 | (0.06) | 0.17 | 0.05 | 0.49 |
| Total expenses | 33.47 | 36.45 | 49.50 | 38.01 | 18.88 | 21.98 | 51.42 | 37.56 |
| EBITDA | 0.02 | 0.55 | 0.11 | (4.08) | (4.58) | (6.85) | (1.95) | (4.35) |
| EBITDA margin | +0.1% | +1.5% | +0.2% | -12.0% | -32.0% | -45.3% | -3.9% | -13.1% |
| Depreciation | 0.71 | 0.62 | (0.24) | 0.86 | 0.86 | 0.85 | (0.23) | 0.71 |
| Interest | 2.73 | 2.46 | 1.81 | 1.39 | 0.95 | 0.63 | 2.13 | 0.39 |
| Profit before tax | (3.40) | (2.51) | (1.29) | (6.33) | (6.45) | (8.16) | (3.80) | (4.96) |
| Tax | (0.66) | (0.40) | 0.42 | (1.48) | (1.51) | (2.04) | (1.65) | (1.03) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 113 | 109 | 39.64 | 30.99 | 60.52 | 52.03 | 13.72 |
| Revenue growth | +3.4% | +175.7% | +27.9% | -48.8% | +16.3% | +279.2% | - |
| Other income | 0.29 | 1.31 | 0.10 | 0.14 | 1.36 | 2.28 | 4.02 |
| Total expenses | 128 | 119 | 49.35 | 38.96 | 59.85 | 48.18 | 21.58 |
| Employee cost | 7.61 | 6.76 | 5.96 | 5.74 | 0.58 | 4.08 | 2.50 |
| EBITDA | (15.32) | (9.82) | (9.71) | (7.97) | 0.67 | 3.85 | (7.86) |
| EBITDA margin | -13.6% | -9.0% | -24.5% | -25.7% | +1.1% | +7.4% | -57.3% |
| Depreciation | 2.32 | 3.61 | 2.66 | 2.05 | 1.59 | 1.20 | 1.00 |
| Interest | 4.82 | 2.23 | 1.59 | 1.49 | 0.92 | 1.78 | 1.09 |
| Profit before tax | (22.17) | (14.35) | (13.86) | (11.37) | (0.48) | 3.15 | (5.93) |
| Tax | (4.61) | (4.05) | (10.39) | 0.20 | 0.12 | 0.21 | (0.15) |
| Net profit | (17.56) | (10.35) | (3.51) | (10.85) | (1.03) | 0.90 | (9.77) |
| Net profit margin | -15.5% | -9.5% | -8.9% | -35.0% | -1.7% | +1.7% | -71.2% |
| EPS (βΉ) | (4.75) | (2.78) | (1.04) | (8.15) | (0.43) | 2.87 | (5.67) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 36.98 | 36.98 | 33.48 | 14.20 | 14.20 | 10.20 | 10.20 |
| Reserves & surplus | (79.67) | (62.62) | (54.17) | (60.40) | (48.83) | (48.22) | (51.15) |
| Shareholders' funds (net worth) | (42.69) | (25.64) | (20.13) | (46.20) | (34.63) | (38.02) | (40.95) |
| Secured loans | 43.11 | 13.92 | 10.86 | 41.99 | 33.86 | 2.85 | 0.50 |
| Unsecured loans | 66.45 | 48.31 | 46.37 | 26.01 | 18.27 | 45.04 | 26.42 |
| Total debt | 110 | 62.23 | 57.23 | 68.00 | 52.13 | 47.89 | 26.92 |
| Total liabilities | 67.86 | 37.67 | 37.73 | 25.45 | 22.73 | 17.88 | 3.12 |
| Assets | |||||||
| Gross block | 74.58 | 61.49 | 50.53 | 46.43 | 36.44 | 31.18 | 25.10 |
| Net block | 47.60 | 36.83 | 29.35 | 27.91 | 19.98 | 16.31 | 11.42 |
| Capital work in progress | 0.00 | 0.23 | 0.00 | 0.00 | 0.34 | 0.65 | 0.00 |
| Investments | 0.47 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 |
| Inventories | 29.42 | 20.51 | 13.72 | 11.71 | 7.28 | 12.11 | 4.25 |
| Sundry debtors | 10.03 | 5.10 | 7.36 | 10.16 | 1.58 | 1.61 | 0.42 |
| Cash & bank balances | 2.15 | 0.12 | 0.10 | 0.11 | 0.16 | 0.45 | 0.12 |
| Loans & advances | 9.83 | 5.21 | 2.93 | 3.04 | 0.55 | 1.77 | 1.98 |
| Total current assets | 51.43 | 30.94 | 24.11 | 25.02 | 9.57 | 15.94 | 6.77 |
| Total current liabilities | 51.83 | 45.14 | 25.46 | 27.15 | 6.99 | 14.65 | 15.49 |
| Net working capital | (0.40) | (14.20) | (1.35) | (2.13) | 2.58 | 1.29 | (8.72) |
| Total assets | 67.86 | 37.67 | 37.73 | 25.45 | 22.73 | 17.88 | 3.12 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.00 | 0.00 | 0.11 | 0.16 | 0.45 | 0.12 | 0.02 |
| Net cash from operating activities | (27.75) | 2.83 | (13.05) | (1.63) | (1.68) | (1.62) | (2.59) |
| Net cash from investing activities | (14.39) | (11.32) | (4.09) | (9.64) | (4.94) | (6.72) | (0.50) |
| Net cash from financing activities | 42.56 | 8.49 | 17.13 | 11.22 | 6.33 | 8.67 | 3.19 |
| Net change in cash | 0.42 | 0.00 | (0.01) | (0.05) | (0.29) | 0.33 | 0.10 |
| Closing cash | 2.15 | 0.12 | 0.10 | 0.11 | 0.16 | 0.45 | 0.12 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +3.4% | +175.7% | +27.9% | -48.8% | +16.3% | +279.2% | - |
| EBITDA growth | -56.0% | -1.1% | -21.8% | -1289.6% | -82.6% | +149.0% | - |
| PBT growth | -54.5% | -3.5% | -21.9% | -2268.8% | - | +9998.0% | -69.4% |
| Net income growth | -69.7% | -194.9% | +67.7% | -953.4% | -214.4% | +109.2% | - |
| Revenue CAGR (3Y) | +53.9% | +21.8% | -8.7% | +31.2% | +43.4% | +59.3% | +19.0% |
| EBITDA CAGR (3Y) | +24.3% | - | - | +0.5% | - | - | +17.5% |
| Profitability & leverage | |||||||
| Net income margin | -15.5% | -9.4% | -8.8% | -37.3% | -1.0% | +5.7% | -42.1% |
| Return on capital employed | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | +7.9% | 0.0% |
| Return on net worth | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -5.8% | 0.0% |
| Debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-term debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest cover | -27.32 | -16.60 | -12.85 | -14.87 | -100.00 | 67.17 | -12.30 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 1.66 | 1.95 | 0.82 | 0.75 | 1.79 | 1.85 | 0.55 |
| Inventory turnover | 4.53 | 6.39 | 3.12 | 3.26 | 6.24 | 6.36 | 2.86 |
| Debtors turnover | 14.93 | 17.54 | 4.53 | 5.28 | 37.94 | 51.26 | 29.51 |
| EPS (βΉ) | (4.75) | (2.78) | (1.04) | (8.15) | (0.43) | 2.87 | (5.67) |
| Dividend per share (βΉ) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (βΉ) | (11.54) | (6.93) | (6.18) | (32.53) | (24.38) | (37.27) | (40.14) |
Similar companies to S S ORGANICS
S S ORGANICS has 3 listed similar companies in our database, 1 of them funded. They include Indoco Remedies, Concord Biotech and BDR Pharmaceuticals Internationals.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| indoco.com | 1947 | Mumbai, India | 6,291 | APIs manufacturing and formulation services are provided in therapeutic segments. | ||
| concordbiotech.com | 2000 | Ahmedabad, India | 1,598 | APIs and enzymes are manufactured through fermentation by the CDMO. | ||
| bdrpharma.com | 2003 | Mumbai, India | $88.16M | 1,864 | APIs and finished products are developed and manufactured. |
Detailed similar companies of S S ORGANICS
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as S S ORGANICS (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 2,062 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 548 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 557 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about S S Organics
Complete news archive for S S ORGANICS
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about S S ORGANICS
S S ORGANICS was founded in 1990.
S S ORGANICS is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
V N Sunanda Reddy is the CEO of S S ORGANICS, as recorded in our data.
S S ORGANICS has 98 employees.
The primary company behind S S ORGANICS, Oxygenta Pharmaceutical Limited, reported revenue of βΉ113 Cr for FY 2026, up 3% year on year.
SS Organics was founded in 1990 in Hyderabad, India, within the pharmaceutical sector. Finished products and active pharmaceutical ingredients (APIs) are produced across categories such as antibiotics, analgesics, respiratory, cardiovascular, gastrointestinal, and antifungal treatments. Manufacturing facilities are certified under ISO 9001:2000 standards, supporting operations focused on these therapeutic areas.
S S ORGANICS's top competitors include Concord Biotech, BDR Pharmaceuticals Internationals and Indoco Remedies.
Yes, S S ORGANICS is publicly traded on BSE under the ticker symbol OXYGENTAPH.
S S ORGANICS operates through Oxygenta Pharmaceutical Limited.
The legal entities of S S ORGANICS currently have 10 directors, including Vedavathi Gangavaram, Veera Reddy Arava, Sidda Reddy Kanuparthi and others.
